167 related articles for article (PubMed ID: 28454526)
1. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
Lee W; Lee S; Bae H; Kim CY; Seong GJ
BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526
[TBL] [Abstract][Full Text] [Related]
2. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
3. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.
Seo du R; Ha SJ
Biomed Res Int; 2015; 2015():435874. PubMed ID: 26557671
[TBL] [Abstract][Full Text] [Related]
5. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
6. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
7. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
[TBL] [Abstract][Full Text] [Related]
8. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
Kuwayama Y; Nomura A
Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
Cho SY; Kim YY; Yoo C; Lee TE
Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
[TBL] [Abstract][Full Text] [Related]
10. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma.
Janulevičienė I; Derkač I; Grybauskiene L; Paulauskaitė R; Gromnickaite R; Kuzmienė L
Clin Ophthalmol; 2012; 6():103-9. PubMed ID: 22275814
[TBL] [Abstract][Full Text] [Related]
11. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness.
Hommer A; Schmidl D; Kromus M; Bata AM; Fondi K; Werkmeister RM; Baar C; Schmetterer L; Garhöfer G
Eur J Ophthalmol; 2018 Jul; 28(4):385-392. PubMed ID: 29592773
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
Karhanová M; Mlčák P; Fryšák Z; Marešová K
Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
Uusitalo H; Kaarniranta K; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
15. Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma.
Hagras SM; Al-Duwailah OKH; Nassief MA; Abdelhameed AG
Indian J Ophthalmol; 2021 Sep; 69(9):2475-2480. PubMed ID: 34427247
[TBL] [Abstract][Full Text] [Related]
16. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
Rossi GC; Blini M; Scudeller L; Ricciardelli G; Depolo L; Amisano A; Bossolesi L; Pasinetti GM; Bianchi PE
J Ocul Pharmacol Ther; 2013 Nov; 29(9):821-5. PubMed ID: 23944905
[TBL] [Abstract][Full Text] [Related]
17. Spanish multicenter tafluprost tolerability study.
Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
[TBL] [Abstract][Full Text] [Related]
18. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy SM
Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
[TBL] [Abstract][Full Text] [Related]
19. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
Konstas AG; Holló G
Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
